Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Xisomab 3G3
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aronora Reports Positive Topline Data From Phase 2 Study of AB023
Details : AB023 is a recombinant antibody that specifically inhibits reciprocal activation of coagulation factors XI (FXI) and XII (FXII) without blocking the hemostatic activity of FXI, which is necessary for normal bleeding control.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 19, 2021
Lead Product(s) : Xisomab 3G3
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB002
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 28, 2019
Lead Product(s) : AB002
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB023
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 02, 2018
Lead Product(s) : AB023
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 05, 2018
Lead Product(s) : Thrombin
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xisomab 3G3
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 31, 2017
Lead Product(s) : Xisomab 3G3
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable